RCM
RYTM icon

RA Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

RA Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$580M Hold
6,666,837
– – 6.14% 3
2025
Q4 		$714M Buy
6,666,837
+985,478
+17% +$105M 7.31% 3
2025
Q3 		$574M Buy
5,681,359
+120,000
+2% +$11.1M 7.07% 2
2025
Q2 		$351M Sell
5,561,359
-523,053
-9% -$32M 5.92% 3
2025
Q1 		$322M Hold
6,084,412
– – 5.38% 3
2024
Q4 		$341M Hold
6,084,412
– – 4.53% 4
2024
Q3 		$319M Hold
6,084,412
– – 3.68% 5
2024
Q2 		$250M Buy
6,084,412
+754,000
+14% +$30.1M 3.3% 5
2024
Q1 		$231M Hold
5,330,412
– – 2.94% 6
2023
Q4 		$245M Sell
5,330,412
-345,655
-6% -$10.9M 3.83% 5
2023
Q3 		$130M Hold
5,676,067
– – 2.56% 7
2023
Q2 		$93.6M Buy
5,676,067
+160,000
+3% +$2.89M 1.77% 16
2023
Q1 		$98.4M Hold
5,516,067
– – 2.23% 15
2022
Q4 		$161M Buy
5,516,067
+45,000
+0.8% +$1.16M 3.26% 6
2022
Q3 		$134M Buy
5,471,067
+600,000
+12% +$11.2M 2.86% 7
2022
Q2 		$20.2M Hold
4,871,067
– – 0.54% 45
2022
Q1 		$56.1M Hold
4,871,067
– – 1.22% 23
2021
Q4 		$48.6M Hold
4,871,067
– – 0.86% 33
2021
Q3 		$63.6M Hold
4,871,067
– – 0.88% 33
2021
Q2 		$71.1M Hold
4,871,067
– – 1.14% 26
2021
Q1 		$104M Buy
4,871,067
+692,000
+17% +$20.1M 1.56% 17
2020
Q4 		$124M Sell
4,179,067
-961,341
-19% -$24.4M 1.74% 14
2020
Q3 		$111M Sell
5,140,408
-69,680
-1% -$1.6M 2.04% 12
2020
Q2 		$116M Sell
5,210,088
-212,224
-4% -$4.14M 2.26% 14
2020
Q1 		$82.5M Hold
5,422,312
– – 2.61% 13
2019
Q4 		$124M Buy
5,422,312
+2,000,000
+58% +$44.4M 3.78% 6
2019
Q3 		$73.9M Buy
3,422,312
+1,537,530
+82% +$33M 4.4% 7
2019
Q2 		$41.5M Hold
1,884,782
– – 2.23% 11
2019
Q1 		$51.7M Sell
1,884,782
-65,550
-3% -$1.88M 2.23% 13
2018
Q4 		$52.4M Hold
1,950,332
– – 3.05% 12
2018
Q3 		$56.9M Buy
1,950,332
+408,589
+27% +$12.9M 3.04% 12
2018
Q2 		$48.2M Buy
+1,541,743
New +$42.2M 3.13% 12

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RA Capital Management's RYTM Position: Q1 2026 in Review

RA Capital Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q1 2026 at 6,666,837 shares worth $580M. The position accounts for 6.14% of the portfolio, ranked #3.

RA Capital Management first reported a position in RYTM in Q2 2018 and has held it in 32 quarters since. The position peaked at $714M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • RA Capital Management held 6,666,837 shares of Rhythm Pharmaceuticals worth $580M as of Q1 2026.
  • RA Capital Management left its Rhythm Pharmaceuticals share count unchanged in Q1 2026.
  • Rhythm Pharmaceuticals made up 6.14% of RA Capital Management's portfolio in Q1 2026, its #3 holding.
  • RA Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • RA Capital Management's Rhythm Pharmaceuticals position peaked at $714M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.